NQO1 and polycystic ovary syndrome: Related to this, the antibreast cancer selective oestrogen receptor modulator, tamoxifen, is known to increase EC risk by inducing oestrogen‐regulated gene expression42 and altering oestrogen metabolism in endometrial cells.43 NQO1 may therefore play a key role in the oestrogen‐related links between EC and PCOS.